<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081610</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH037-0119/I</org_study_id>
    <nct_id>NCT04081610</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution</brief_title>
  <acronym>PRO-037</acronym>
  <official_title>Phase I Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Compared to Lagricel® Ofteno Single Dose on the Ocular Surface of Clinically Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design: Phase I clinical trial, single-center, controlled, parallel group, open,&#xD;
      randomized.&#xD;
&#xD;
      Number of subjects: n = 34 evaluable subjects, 17 evaluable subjects per group (both eyes).&#xD;
&#xD;
      Estimated duration of the study: 5 months&#xD;
&#xD;
      Therapeutic indication: Eye lubricant Use: Dry Eye&#xD;
&#xD;
      Objective:To evaluate the safety and tolerability of Lagricel® Ofteno multidose manufactured&#xD;
      by Laboratorios Sophia on the ocular surface of clinically healthy subjects.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      H0 = Lagricel® Ofteno multidose ophthalmic solution has a safety and tolerability profile&#xD;
      similar to Lagricel® Ofteno single dose in healthy subjects.&#xD;
&#xD;
      H1 = Lagricel® Ofteno multidose ophthalmic solution has a different safety and tolerability&#xD;
      profile than Lagricel® Ofteno single dose in healthy subjects.&#xD;
&#xD;
      Main inclusion criteria: Clinically healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Actual">November 13, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single-center, controlled, parallel group, open, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Adverse Events (AEs)</measure>
    <time_frame>during the 10 days of evaluation, including the safety call (day 11).</time_frame>
    <description>the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eye Comfort Index (ECI)</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity (VA)</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelial Defects (ED) Fluorescein Stain</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epithelial Defects (ED) Green Lissamine</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperemia (CH)</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Lagricel® Ofteno Multidose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lagricel® Ofteno Single dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lagricel ofteno multidose</intervention_name>
    <description>Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
Route of administration: Ophthalmic</description>
    <arm_group_label>Lagricel® Ofteno Multidose</arm_group_label>
    <other_name>sodium hyaluronate 0.4%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lagricel ofteno single dose</intervention_name>
    <description>Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
Route of administration: Ophthalmic</description>
    <arm_group_label>Lagricel® Ofteno Single dose</arm_group_label>
    <other_name>sodium hyaluronate 0.4%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be clinically healthy&#xD;
&#xD;
          -  To have the ability to voluntarily grant your signed informed consent&#xD;
&#xD;
          -  To have the willingness to comply with scheduled visits treatment plan and other study&#xD;
             procedures&#xD;
&#xD;
          -  Women in reproductive age should ensure the continuation (initiated ≥ 30 days prior to&#xD;
             the signing of the informed consent) to use a hormonal contraceptive method or&#xD;
             intrauterine device during the study period.&#xD;
&#xD;
          -  To have a better corrected visual acuity of 20/30 or better in both eyes.&#xD;
&#xD;
          -  To have vital signs in normal parameters.&#xD;
&#xD;
          -  To have an intraocular pressure between ≥10 and ≤ 21 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  To be user of ophthalmic topical products of any kind.&#xD;
&#xD;
          -  To be user of medicines, or herbal products, by any other route of administration.&#xD;
&#xD;
          -  In the case of women: being pregnant, breastfeeding or planning to get pregnant in the&#xD;
             study period.&#xD;
&#xD;
          -  Having participated in clinical research studies 90 days prior to inclusion in this&#xD;
             study.&#xD;
&#xD;
          -  Having previously participated in this same study.&#xD;
&#xD;
          -  To be a user of contact lenses and can not suspend their use during the study.&#xD;
&#xD;
          -  Having initiated the use of hormonal contraceptives or intrauterine devices, 30 days&#xD;
             prior to inclusion in the present study.&#xD;
&#xD;
          -  To have a history of any chronic degenerative disease.&#xD;
&#xD;
          -  Having inflammatory or infectious disease, active at the time of admission to the&#xD;
             study.&#xD;
&#xD;
          -  Having injuries or unresolved injuries at the time of admission to the study.&#xD;
&#xD;
          -  Having a history of any type of eye surgery.&#xD;
&#xD;
          -  Having undergone surgical procedures, not ophthalmological, in the last 3 months.&#xD;
&#xD;
          -  To be or to have an immediate family member (for example: spouse, parent / legal&#xD;
             guardian, brother or child) who is part of the research site staff or the sponsor who&#xD;
             participates directly in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Baiza Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biomedical research G &amp; LS de RL de CV</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>March 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2021</results_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry eye</keyword>
  <keyword>eye lubricant</keyword>
  <keyword>sodium hyaluronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Laboratorios Sophia, S.A. de C.V., serving as the sponsor of the study, assumes full responsibility for its function and retains exclusive ownership rights over the results of the study.&#xD;
The principal investigator undertakes not to publish or communicate data collected from the study, unless there is prior written agreement of Laboratorios Sophia, S.A. de C.V.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04081610/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lagricel® Ofteno Multidose</title>
          <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
        </group>
        <group group_id="P2">
          <title>Lagricel® Ofteno Single Dose</title>
          <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lagricel® Ofteno Multidose</title>
          <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
        </group>
        <group group_id="B2">
          <title>Lagricel® Ofteno Single Dose</title>
          <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="6.6"/>
                    <measurement group_id="B2" value="29.7" spread="7.9"/>
                    <measurement group_id="B3" value="29.0" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Presence of Adverse Events (AEs)</title>
        <description>the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent</description>
        <time_frame>during the 10 days of evaluation, including the safety call (day 11).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Adverse Events (AEs)</title>
          <description>the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Compare the safety of the Lagricel® Ofteno multi-dose formulation against Lagricel® Ofteno unit doses manufactured by Sophia Laboratories S.A. of C.V. through the incidence of AD.</non_inferiority_desc>
            <p_value>0.409</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Eye Comfort Index (ECI)</title>
        <description>It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Eye Comfort Index (ECI)</title>
          <description>It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inicial ECI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.98" lower_limit="20.31" upper_limit="39.66"/>
                    <measurement group_id="O2" value="27.28" lower_limit="21.38" upper_limit="33.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final ECI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.76" lower_limit="12.31" upper_limit="25.21"/>
                    <measurement group_id="O2" value="18.01" lower_limit="11.57" upper_limit="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Compare the tolerability of the Lagricel® Ofteno multi-dose formulation against Lagricel® Ofteno unit-dose manufactured by Sophia Laboratories S.A. of C.V. using the ICO score.</non_inferiority_desc>
            <p_value>0.442</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Final vs initial Eye Comfort Index</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>F=2.606, 15.926</non_inferiority_desc>
            <p_value>0.009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final vs initial Eye Comfort Index</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>F=3.051, 19.336</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity (VA)</title>
        <description>Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity (VA)</title>
          <description>Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.</description>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Final VA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" spread="0.05"/>
                    <measurement group_id="O2" value="0.989" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Initial VA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" spread="0.09"/>
                    <measurement group_id="O2" value="0.989" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Compare the safety of the Lagricel® Ofteno multi-dose formulation against Lagricel® Ofteno unit doses manufactured by Sophia Laboratories S.A. of C.V. through changes in BCVA.</non_inferiority_desc>
            <p_value>0.904</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Final vs initial VA</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>F=-1.414, 1.061</non_inferiority_desc>
            <p_value>0.157</p_value>
            <method>Sign test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final vs initial VA</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epithelial Defects (ED) Fluorescein Stain</title>
        <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <population>Initial Fluorescein Staining Grade 0 (Lagricel® Ofteno Multidose n=22; Lagricel® Ofteno Single dose n=26) Initial Fluorescein Staining Grade 1 (Lagricel® Ofteno Multidose n=8; Lagricel® Ofteno Single dose n=8) Initial Fluorescein Staining Grade 2 (Lagricel® Ofteno Multidose n=2; Lagricel® Ofteno Single dose n=2)</population>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Epithelial Defects (ED) Fluorescein Stain</title>
          <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
          <population>Initial Fluorescein Staining Grade 0 (Lagricel® Ofteno Multidose n=22; Lagricel® Ofteno Single dose n=26) Initial Fluorescein Staining Grade 1 (Lagricel® Ofteno Multidose n=8; Lagricel® Ofteno Single dose n=8) Initial Fluorescein Staining Grade 2 (Lagricel® Ofteno Multidose n=2; Lagricel® Ofteno Single dose n=2)</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Final Fluorescein Staining Grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Final Fluorescein Staining Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Compare the safety of the Lagricel® Ofteno multi-dose formulation against Lagricel® Ofteno unit doses manufactured by Sophia Laboratories S.A. of C.V. by changes in corneal and conjunctival staining with fluorescein.</non_inferiority_desc>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Final vs initial fluorescein staining</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-squared (2)= 6.400</non_inferiority_desc>
            <p_value>0.041</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-squared (2)=0.814</non_inferiority_desc>
            <p_value>0.665</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epithelial Defects (ED) Green Lissamine</title>
        <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <population>Initial Lissamine Green Staining Grade 0 (Lagricel® Ofteno Multidose n=24; Lagricel® Ofteno Single dose n= 23 Initial Lissamine Green Staining Grade 1 (Lagricel® Ofteno Multidose n=6; Lagricel® Ofteno Single dose n= 11 Initial Lissamine Green Staining Grade 2 (Lagricel® Ofteno Multidose n=1; Lagricel® Ofteno Single dose n= 2 Initial Lissamine Green Staining Grade 3 (Lagricel® Ofteno Multidose n=1; Lagricel® Ofteno Single dose n= 0)</population>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Epithelial Defects (ED) Green Lissamine</title>
          <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
          <population>Initial Lissamine Green Staining Grade 0 (Lagricel® Ofteno Multidose n=24; Lagricel® Ofteno Single dose n= 23 Initial Lissamine Green Staining Grade 1 (Lagricel® Ofteno Multidose n=6; Lagricel® Ofteno Single dose n= 11 Initial Lissamine Green Staining Grade 2 (Lagricel® Ofteno Multidose n=1; Lagricel® Ofteno Single dose n= 2 Initial Lissamine Green Staining Grade 3 (Lagricel® Ofteno Multidose n=1; Lagricel® Ofteno Single dose n= 0)</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Final Lissamine Green Staining Grade 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Final Lissamine Green Staining Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Compare the safety of the Lagricel® Ofteno multi-dose formulation against Lagricel® Ofteno unit doses manufactured by Sophia Laboratories S.A. of C.V. by changes of corneal and conjunctival staining with lysamine green.</non_inferiority_desc>
            <p_value>0.713</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Final vs initial lissamine green staining</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-squared (3)=14.345</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final vs initial lissamine green staining</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-squared (2)=0.506</non_inferiority_desc>
            <p_value>0.777</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Hyperemia (CH)</title>
        <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <population>Initial conjunctival hyperemia (Lagricel® Ofteno Multidose n=26; Lagricel® Ofteno Single dose n=28)</population>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Hyperemia (CH)</title>
          <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
          <population>Initial conjunctival hyperemia (Lagricel® Ofteno Multidose n=26; Lagricel® Ofteno Single dose n=28)</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hyperemia grade 0 (Normal)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperemia grade 1 (Very Light)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperemia grade 2 (Light)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperemia grade 3 (Mild)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperemia grade 4 (Moderate)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hyperemia grade 5 (Severe)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Compare the safety of the Lagricel® Ofteno multi-dose formulation against Lagricel® Ofteno unit doses manufactured by Sophia Laboratories S.A. of C.V. by changes in conjunctival hyperemia.</non_inferiority_desc>
            <p_value>1.000</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Final vs initial conjunctival hyperemia</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>F=4.167, 1</non_inferiority_desc>
            <p_value>0.031</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final vs initial conjunctival hyperemia</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>No significant change was observed.</non_inferiority_desc>
            <p_value>1.000</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis</title>
        <description>It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <population>Initial Chemosis (Lagricel® Ofteno Multidose, n=0; Lagricel® Ofteno Single dose, n=0)</population>
        <group_list>
          <group group_id="O1">
            <title>Lagricel® Ofteno Multidose</title>
            <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
          <group group_id="O2">
            <title>Lagricel® Ofteno Single Dose</title>
            <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis</title>
          <description>It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening</description>
          <population>Initial Chemosis (Lagricel® Ofteno Multidose, n=0; Lagricel® Ofteno Single dose, n=0)</population>
          <units>Eyes</units>
          <param>Count of Units</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Final chemosis present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Final chemosis absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored throughout the study, which lasted about 1 month and 15 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lagricel® Ofteno Multidose</title>
          <description>Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno multidose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
        </group>
        <group group_id="E2">
          <title>Lagricel® Ofteno Single Dose</title>
          <description>Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia&#xD;
lagricel ofteno single dose: - Dosage: 1 drop 4 times a day per 7 days, both eyes&#xD;
- Route of administration: Ophthalmic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>burning eyes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>eye itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>foreign body sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Only the sponsor has the decision to disseminate or publish the information obtained from the investigation and the PIs involved must submit a formal request to the sponsor if they are willing to disseminate or publish such information, they may only publish them if they have the written authorization of the sponsor (Laboratoios Sophia S.A. de C.V.).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alejandra Sanchez-Rios</name_or_title>
      <organization>Laboratorios Sophia</organization>
      <phone>+52 (33) 3001 4200 ext 1190</phone>
      <email>alejandra.sanchez@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

